Eva Rubin, MD
Pulmonary Disease · Massapequa, NYNPI 1952437162
Payments from drug & device makers
Across 179 payments — averaging $83.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$6K
- AstraZeneca$1K
- Bayer$1K
- Boehringer Ingelheim$959
- GSK$933
- Amgen$485
- plus $4K from 26 others
What the payments were for
- Consulting fees$5,10034%
- Speaking & faculty fees$1,0807%
- Travel & lodging$7565%
- Food & beverage$7,57351%
- Education$4063%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 14 | $6,441 |
| AstraZeneca(2 entities) | 25 | $1,463 |
| Bayer | 2 | $1,092 |
| Boehringer Ingelheim | 12 | $959 |
| GSK | 26 | $933 |
| Amgen | 4 | $485 |
| Novartis | 15 | $473 |
| Actelion Pharmaceuticals US, Inc. | 5 | $449 |
| Merck | 20 | $420 |
| Sanofi | 8 | $345 |
| Johnson & Johnson(2 entities) | 5 | $307 |
| Olympus America Inc. | 2 | $269 |
| Daiichi Sankyo Inc. | 9 | $202 |
| Abbott | 2 | $192 |
| Sanofi-aventis U.S. LLC | 5 | $149 |
| Pulmonx Corporation | 1 | $125 |
| Regeneron Healthcare Solutions, Inc. | 1 | $125 |
| Boston Scientific | 3 | $71 |
| Insmed, Inc. | 3 | $66 |
| Lexicon Pharmaceuticals, Inc. | 3 | $53 |
| Baxter Healthcare | 2 | $53 |
| Amarin Pharma, Inc. | 2 | $41 |
| Mallinckrodt Hospital Products Inc. | 1 | $33 |
| Lilly USA, LLC | 1 | $27 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $25 |
| Exact Sciences | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Inspire Medical Systems, Inc. | 1 | $17 |
| Electromed, Inc. | 1 | $16 |
| Bardy Diagnostics, Inc. | 1 | $16 |
| Cumberland Pharmaceuticals, Inc. | 1 | $15 |
| Philips North America LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TYVASO$6,006
- Adempas$1,080
- TRELEGY ELLIPTA$489
- OFEV$369
- DUPIXENT$253
- AIRSUPRA$250
- FASENRA$250
- TEZSPIRE$244
- Repatha$244
- ENTRESTO$243
- BREZTRI$239
- CardioMEMS HF System$167
- SPiN Vision Video Processor$144
- UPTRAVI$125
- OPSUMIT$125
- Pulmonx Endobronchial Valve EBV$125
- SOLIRIS$125
- XARELTO$125
- Monarch Platform$125
- NUCALA$123
How this compares
$14,915 in reported general payments places this provider in the 80th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 213 | $171,355 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 109 | $80,120 |
| Spiriva RespimatTiotropium Bromide | 104 | $74,635 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 91 | $50,571 |
| Breo ElliptaFluticasone/Vilanterol | 69 | $32,253 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 36 | $28,960 |
| Incruse ElliptaUmeclidinium Bromide | 43 | $23,793 |
| Roflumilast | 225 | $20,127 |
| SymbicortBudesonide/Formoterol Fumarate | 28 | $7,807 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 222 | $5,943 |
| Advair HfaFluticasone Propion/Salmeterol | 19 | $5,571 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 26 | $5,176 |
| Varenicline Tartrate | 27 | $4,111 |
| Montelukast Sodium | 155 | $1,596 |
| Ventolin HfaAlbuterol Sulfate | 20 | $1,443 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $933 | $277,971416 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $959 | $103,594140 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,463 | $87,927137 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in Massapequa
- Linda RogersNew York$7.1M
- Maria PadillaNew York$3.6M
- R WhiteRochester$3.1M
- Juan WisniveskyNew York$3M
- Bushra MinaNew York$2.5M
- Robert KanerNew York$2.3M
- Negin HajizadehGreenport$2M
- Doreen Addrizzo-HarrisNew York$1.9M
- Sherif El BayadiSyracuse$1.9M
- Daniel LachantRochester$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.